Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
Recap by typeshit. Full story at Dr Almerie, MD.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
A clinical piece for foot and limb care providers on how GLP-1 drugs relate to the lower extremity. Only the title is available.
He describes a case where a product sourced from neither Eli Lilly nor a compounding pharmacy was followed by liver failure within six days.
The pharmacists' group says the drug looks promising but urges patients to understand what they risk with unofficial sources, and points to its SafeMedication site.
Loading…